Data compiled by Redley Lamar · ChainSifter Intelligence
8Suppliers
10Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Eledon Pharmaceuticals, Inc. (ELDN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
22Total relationships
4Distinct source URLs
8High confidence
0.758Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Eledon Pharmaceuticals, Inc. Suppliers
Ticker
Name
Confidence
Evidence
LONZA-SALES-AG-INC
LONZA-SALES-AG-INC
90%
we have acquired rights to tegoprubart and other product candidates through a license agreement with The ALS Therapy Development Institute and a manufacturing know-how rights license agreement with L…
THE-ALS-THERAPY-DEVELOPMENT-FOUNDATION-INC
THE-ALS-THERAPY-DEVELOPMENT-FOUNDATION-INC
90%
we have acquired rights to tegoprubart and other product candidates through a license agreement with The ALS Therapy Development Foundation, Inc.
THE-ALS-THERAPY-DEVELOPMENT-INSTITUTE
THE-ALS-THERAPY-DEVELOPMENT-INSTITUTE
90%
In May 2015, Anelixis executed a License Agreement (the “Agreement”), which is an exclusive patent rights agreement with ALS Therapy Development Institute (“ALS TDI”) for certain patents and “know-ho…
Reciprocal relationship from NCEL graph: gulatory authority approvals to do so. The facilities and quality systems of some or all of its collaborators and third-party contractors must pass a pre-appr…
Reciprocal relationship from ORANY graph: Reciprocal relationship from ELDN graph: ation fees for supplemental applications with clinical data. Drug manufacturers are subject to periodic unannounced …
ation fees for supplemental applications with clinical data. Drug manufacturers are subject to periodic unannounced inspections by the FDA and state agencies for compliance with cGMP requirements. Ch…
SNYNF
Sanofi
72%
asures are also imposed by healthcare laws and regulations in international jurisdictions and in those jurisdictions we face the same issues as in the United States regarding difficulty and cost for …
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from ELDN graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ELDN graph: Reciprocal relationship from SNYN…
Eledon Pharmaceuticals, Inc. Customers
Ticker
Name
Confidence
Evidence
COASTLANDS-CAPITAL-PARTNERS-LP
COASTLANDS-CAPITAL-PARTNERS-LP
80%
Coastlands Capital agreed to exchange 4,203,764 shares of the Company’s common stock for a pre-funded warrant to purchase an aggregate of 4,203,764 shares of common stock
Reciprocal relationship from ORANY graph: Reciprocal relationship from ELDN graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from ELDN graph: ation fees for supplemental appli…
ation fees for supplemental applications with clinical data. Drug manufacturers are subject to periodic unannounced inspections by the FDA and state agencies for compliance with cGMP requirements. Ch…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from ELDN graph: asures are also imposed by healthcare laws and regulations in international jurisdictions and in those jurisdictions…
SNYNF
Sanofi
72%
asures are also imposed by healthcare laws and regulations in international jurisdictions and in those jurisdictions we face the same issues as in the United States regarding difficulty and cost for …
ANELIXIS-THERAPEUTICS-INC
ANELIXIS-THERAPEUTICS-INC
62%
be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to all…
CORPORATE-INFORMATION-OTIC-PHARMA-LTD
CORPORATE-INFORMATION-OTIC-PHARMA-LTD
62%
be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to all…
LONZA-SALES-AG-INC
LONZA-SALES-AG-INC
62%
ws, restrictions, and other regulatory measures imposed in international jurisdictions present similar challenges to those in the United States, including increased difficulty and cost in obtaining m…
NOVUS-THERAPEUTICS-INC
NOVUS-THERAPEUTICS-INC
62%
be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to all…
TOKAI-PHARMACEUTICALS-INC
TOKAI-PHARMACEUTICALS-INC
62%
be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to all…
Eledon Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ELDN-DEBT
Debt stack $555,000
90%
Market cache reports total debt of $555,000.
ELDN-DEBT-9265
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2016-12-31.
ELDN-DEBT-9264
Warrants outstanding: 0.001
90%
xbrl warrant detail from xbrl 2025-12-31.
Eledon Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Eledon Pharmaceuticals, Inc..
Eledon Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
ELDN-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 124 tracked holders.
Eledon Pharmaceuticals, Inc. Extended Supply Chain Network
